Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac

International Journal of Nanomedicine

Volumn 12, Issue , 2017, Pages 1305-1315

  Sudha, Thangirala ^a   Bharali, Dhruba J ^a   Yalcin, Murat ^a,b   Darwish, Noureldien H E ^a,c   Coskun, Melis Debreli ^a,b   Keating, Kelly A ^a   Lin, Hung Yun ^d   Davis, Paul J ^a,e   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ULUDAG UNIVERSITY   (Turkey)

^c MANSOURA UNIVERSITY   (Egypt)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Doxorubicin; Integrin; Nanoparticle; Nanotetrac; NDAT; Paclitaxel; Tetraiodothyroacetic acid; Xenografts

Indexed keywords

DIAMINO TETRAIODOTHYROACETIC ACID NANOPARTICLE; DOCETAXEL; DOXORUBICIN; NANOPARTICLE; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; TETRAIODOTHYROACETIC ACID; THYROXINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL VIABILITY; CONTROLLED STUDY; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG UPTAKE; EX VIVO STUDY; FEMALE; IN VIVO STUDY; MOUSE; NANOENCAPSULATION; NONHUMAN; PANCREAS CANCER; PARTICLE SIZE; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; BREAST NEOPLASMS; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; HUMAN; NUDE MOUSE; PANCREATIC NEOPLASMS; PHOTON CORRELATION SPECTROSCOPY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DYNAMIC LIGHT SCATTERING; FEMALE; HUMANS; LACTIC ACID; MICE, NUDE; NANOPARTICLES; PACLITAXEL; PANCREATIC NEOPLASMS; PARTICLE SIZE; POLYGLYCOLIC ACID; THYROXINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85013472911     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S123742     Document Type: Article

References (38)

1. Matsusaka S, Lenz HJ. Pharmacogenomics of fluorouracil-based chemotherapy toxicity. Expert Opin Drug Metab Toxicol. 2015; 11(5):811–821.
2. Chan ES, Cronstein BN. Mechanisms of action of methotrexate. Bull Hosp Jt Dis. 2013;71(suppl 1):S5–S8.
3. Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 2014;10(4):853–858.
4. Barbuti AM, Chen ZS. Paclitaxel through the ages of anticancer therapy: exploring its role in chemoresistance and radiation therapy. Cancers. 2015;7(4):2360–2371.
5. Dilruba S, Kalayda GV. Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol. 2016;77(6):1103–1124.
6. Ulbrich K, Hola K, Subr V, Bakandritsos A, Tucek J, Zboril R. Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies. Chem Rev. 2016;116(9):5338–5431.
7. Arosio D, Casagrande C. Advancement in integrin facilitated drug delivery. Adv Drug Deliv Rev. 2016;97:111–143.
8. Linton SS, Sherwood SG, Drews KC, Kester M. Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016;8(2):208–222.
9. Oberoi RK, Parrish KE, Sio TT, Mittapalli RK, Elmquist WF, Sarkaria JN. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Neuro Oncol. 2016;18(1): 27–36.
10. Soudy R, Byeon N, Raghuwanshi Y, Ahmed S, Lavasanifar A, Kaur K. Engineered peptides for applications in cancer targeted drug delivery and tumor detection. Mini Rev Med Chem. Epub 2016 Feb 19.
11. Yang Y, Yu C. Advances in silica based nanoparticles for targeted cancer therapy. Nanomedicine. 2016;12(2):317–332.
12. Davis PJ, Goglia F, Leonard JL. Nongenomic actions of thyroid hormone. Nat Rev Endocrinol. 2016;12(2):111–121.
13. Bharali DJ, Yalcin M, Davis PJ, Mousa SA. Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. Nanomedicine (Lond). 2013;8(12): 1943–1954.
14. van der Meel R, Vehmeijer LJ, Kok RJ, Storm G, van Gaal EV. Ligandtargeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev. 2013;65(10):1284–1298.
15. Iyer AK, Singh A, Ganta S, Amiji MM. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev. 2013;65(13–14):1784–1802.
16. Alibolandi M, Abnous K, Hadizadeh F, et al. Dextran-poly lactide-coglycolide polymersomes decorated with folate-antennae for targeted delivery of docetaxel to breast adenocarcinima in vitro and in vivo. J Control Release. 2016;241:45–56.
17. Fasehee H, Dinarvand R, Ghavamzadeh A, et al. Delivery of disulfiram into breast cancer cells using folate-receptor-targeted PLGA-PEG nanoparticles: in vitro and in vivo investigations. J Nanobiotechnology. 2016;14:32.
18. Chen Z, Patel JM, Noble PW, et al. A lupus anti-DNA autoantibody mediates autocatalytic, targeted delivery of nanoparticles to tumors. Oncotarget. 2016;7(37):59965–59975.
19. Zhang X, Li J, Yan M. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for codelivery of cisplatin and doxorubicin. Drug Dev Ind Pharm. 2016;42(10): 1590–1599.
20. Di-Wen S, Pan GZ, Hao L, et al. Improved antitumor activity of epirubicin-loaded CXCR4-targeted polymeric nanoparticles in liver cancers. Int J Pharm. 2016;500(1–2):54–61.
21. Zhang X, Wang Q, Qin L, et al. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer. Drug Deliv. 2016; 23(8):2936–2945.
22. Wang C, Su L, Wu C, Wu J, Zhu C, Yuan G. RGD peptide targeted lipid-coated nanoparticles for combinatorial delivery of sorafenib and quercetin against hepatocellular carcinoma. Drug Dev Ind Pharm. 2016;42(12):1938–1944.
23. Sudha T, Bharali DJ, Yalcin M, et al. Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diaminotetrac. Nanomedicine (Lond). 2017;12(3):195–205.
24. Jin C, Li H, He Y, et al. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo. J Cancer Res Clin Oncol. 2010;136(2):267–274.
25. Wang Y, Zhang H, Hao J, Li B, Li M, Xiuwen W. Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect. Drug Deliv. 2016;23(4): 1398–1403.
26. Rebbaa A, Chu F, Davis FB, Davis PJ, Mousa SA. Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent. Angiogenesis. 2008;11(3):269–276.
27. Davis PJ, Incerpi S, Lin HY, Tang HY, Sudha T, Mousa SA. Thyroid hormone and p-glycoprotein in tumor cells. Biomed Res Int. 2015;2015:168427.
28. Siddiqui IA, Bharali DJ, Nihal M, et al. Excellent anti-proliferative and pro-apoptotic effects of (-)-epigallocatechin-3-gallate encapsulated in chitosan nanoparticles on human melanoma cell growth both in vitro and in vivo. Nanomedicine. 2014;10(8):1619–1626.
29. Yalcin M, Bharali DJ, Lansing L, et al. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res. 2009;29(10):3825–3831.
30. Israel M, Pegg WJ, Wilkinson PM, Garnick MB. Liquid chromatographic analysis of adriamycin and metabolites in biological fluids. J Liq Chromatogr. 1978;1(6):795–809.
31. Davis PJ, Davis FB, Mousa SA, Luidens MK, Lin HY. Membrane receptor for thyroid hormone: physiologic and pharmacologic implications. Annu Rev Pharmacol Toxicol. 2011;51:99–115.
32. Davis PJ, Glinsky GV, Lin HY, et al. Cancer cell gene expression modulated from plasma membrane integrin αvβ3 by thyroid hormone and nanoparticulate tetrac. Front Endocrinol (Lausanne). 2014;5:240.
33. Bergh JJ, Lin HY, Lansing L, et al. Integrin αvβ3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogenactivated protein kinase and induction of angiogenesis. Endocrinology. 2005;146(7):2864–2871.
34. Yalcin M, Lin HY, Sudha T, et al. Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles. Horm Cancer. 2013;4(3):176–185.
35. Mousa SA, Yalcin M, Bharali DJ, et al. Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and its growth in xenografts. Lung Cancer. 2012;76(1):39–45.
36. Glinskii AB, Glinsky GV, Lin HY, et al. Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle. 2009;8(21):3562–3570.
37. Lin HY, Sun M, Tang HY, et al. L-thyroxine vs. 3,5,3′-triiodo-l-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol. 2009;296(5):C980–C991.
38. Lin HY, Landersdorfer CB, London D, et al. Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system. PLoS Comput Biol. 2011;7(2):e1001073.